It's always great to have more responses but you don't see the...

It's always great to have more responses but you don't see the collective data as fantastic?

It's a terribly hard basket to recruit by the sounds of it, top that off with PTX-100 being their 3rd or 4th line of treatment. It's always going to be hard to have full sets of effective data for many of the recruited patients.

The table that @GH1971 kindly posted yesterday from the announcement shows that PTX-100 is 2 to 3 times above the median benchmark for a registrational trial.

I believe PTX-100 is sitting around 40% effective? Which is above the most effective lines of treatment currently available unless I'm wrong? Where they are also only getting 5-6 months extended life on average for those that respond vs PTX-100 average of 12.2 months.

So the final PTX-100 readout is more effective, for twice as long as the current frontline treatments? And our patients are almost dead after failing the first lines!

It will be great to see what PTX-100 can do as a frontline or combination therapy in recently diagnosed TCL patients.

I'm not worried at all about the dump in share price, I think the swing traders and funds have closed positions given the wait time between now and the FDA's decision on a registrational trial. Regardless of the readout results, there was a lot of capital pumped in the last month that was never going to sit idle in our market cap over the new year.